Bausch Health Companies (BHC) EBITDA Margin (2009 - 2026)
Bausch Health Companies' (BHC) quarterly EBITDA Margin came in at 25.95% in Q2 2026, up 840.0% year-over-year from 2.76% in Q2 2025, and up 168.94% quarter-over-quarter from 37.64% in Q1 2026.
Powered by 
Analysis
Bausch Health Companies (BHC) EBITDA Margin (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed EBITDA Margin across 18 years of filings, most recently posting 25.95% for Q2 2026.
- In Q2 2026, EBITDA Margin rose 840.0% year-over-year to 25.95%; the TTM figure through Jun 2026 stood at 8.14% (down 805.0% YoY), while the FY2025 annual figure was 17.66%, up 160.0% from the prior year.
- EBITDA Margin came in at 25.95% for Q2 2026 at Bausch Health Companies, up from 37.64% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 25.95% in Q2 2026 to a low of 37.64% in Q1 2026.
- Average EBITDA Margin over 5 years is 10.54%, with a median of 13.96% recorded in 2024.
- Year-over-year, EBITDA Margin surged 2579 bps in 2023 and tumbled 4986 bps in 2026.
- Over 5 years, EBITDA Margin stood at 10.76% in 2022, then jumped by 240 bps to 15.03% in 2023, then soared by 45 bps to 21.81% in 2024, then fell by 22 bps to 16.95% in 2025, then soared by 53 bps to 25.95% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 25.95% in Q2 2026, 37.64% in Q1 2026, and 16.95% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 25.95% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 15.21% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -134.08% |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 9.72% |
| 10 | NutriBand | 72.57 Mn | 69.15 Mn | 181,874.00 | -203.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.95% |
| Mar 31, 2026 | -37.64% |
| Dec 31, 2025 | 16.95% |
| Sep 30, 2025 | 23.09% |
| Jun 30, 2025 | 17.55% |
| Mar 31, 2025 | 12.22% |
| Dec 31, 2024 | 21.81% |
| Sep 30, 2024 | 12.67% |
| Jun 30, 2024 | 16.19% |
| Mar 31, 2024 | 13.05% |
| Dec 31, 2023 | 15.03% |
| Sep 30, 2023 | 0.63% |
| Jun 30, 2023 | 19.01% |
| Mar 31, 2023 | 9.00% |
| Dec 31, 2022 | -10.76% |
| Sep 30, 2022 | 11.93% |
| Jun 30, 2022 | 8.19% |
| Mar 31, 2022 | 14.86% |
| Dec 31, 2021 | 16.71% |
| Sep 30, 2021 | 27.19% |